Cell Technology's Im Vert
Biological response modifier granted orphan status by FDA for use in treating primary brain cancer. Currently in Phase II study at 10 U.S. centers, the anticancer product could reach the market in late 1989 or early 1990, Boulder, Colo.-based Cell Technology says.
You may also be interested in...
Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.
Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research
Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.
Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.